Physician profile
Curtis J Wolfe
NPI 1881645224
$1,971.52
in general payments reported to CMS, 2019-2025
26 companies · $778 in 2025
The $778 reported for 2025 was more than what 80% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $155 · 2024: $1,038 · 2025: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,971.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $310.70 | 2023-2025 | Vraylar |
| Supernus Pharmaceuticals, INC. | $190.69 | 2024 | Qelbree |
| Novo Nordisk INC | $174.80 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $147.93 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $129.24 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $99.49 | 2024-2025 | Rexulti |
| Pfizer INC. | $89.52 | 2023-2025 | |
| Eisai INC. | $76.40 | 2024-2025 | |
| Exact Sciences Corporation | $76.10 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.45 | 2023-2024 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $71.31 | 2023-2024 | Ajovy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $71.23 | 2024-2025 | Caplyta |
| Shield Therapeutics INC | $68.19 | 2025 | |
| Ardelyx, INC. | $60.65 | 2024 | Ibsrela |
| Lundbeck LLC | $45.42 | 2024 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $42.24 | 2024-2025 | Mounjaro, Zepbound |
| Noven Therapeutics, LLC | $41.24 | 2023-2024 | Xelstrym |
| Boston Scientific Corporation | $32.10 | 2025 | Watchman Flx |
| Astellas Pharma US INC | $29.79 | 2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $28.60 | 2024 | Voquezna |
| Dexcom, INC. | $25.48 | 2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $20.18 | 2024 | Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $19.87 | 2024 | Quviviq |
| Amgen INC. | $15.85 | 2025 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.55 | 2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $13.50 | 2025 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtis Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.